invoX Pharma
invoX Pharma is a private biopharmaceutical company that develops and partners drug-device combination products built on its proprietary Softhaler® soft-mist inhalation platform, targeting chronic respiratory diseases for pharmaceutical and biotech partners globally.
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What invoX Pharma does
invoX Pharma is a privately held, UK-incorporated biopharmaceutical company founded in March 2021 and headquartered operationally at the Bioville campus in Diepenbeek, Belgium, with a registered office in London. The company is built around Softhaler®, a proprietary next-generation soft-mist inhalation (SMI) platform that mechanically converts propellant-free, water-based liquid formulations into ultra-fine mist for deep-lung delivery. The platform supports both innovative and generic drug-device combination products and is positioned to address indications including COPD, asthma, pulmonary arterial hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis, with research extending into delivery of peptides, nucleic acids, enzymes, and antibodies.
invoX monetises the platform through four interlocking streams: co-development partnerships with pharmaceutical and biotech firms that leverage Softhaler® for late-stage or approved respiratory medicines; licensing of internal pipeline programmes and platform technology; contract manufacturing services spanning device manufacture, assembly, sterile fill & finish, and packaging from development through commercial scale; and, prospectively, commercialisation of generic and innovative drug-device combination products. The company operates a unique end-to-end supply chain with its own bespoke manufacturing equipment, and in October 2024 designated H&T Presspart (Heitkamp & Thumann Group) as its industrialisation and manufacturing partner, with sub-assembly production in a dedicated clean room in Tarragona, Spain.
In March 2023, invoX acquired US-based F-star Therapeutics Inc. for $161 million, expanding its pipeline into head and neck cancer therapeutics and adding a US operating footprint. The company also holds a minor collaboration with Insilico Medicine (October 2023) for deep learning applications in drug discovery. invoX serves a narrow enterprise customer base — primarily large pharmaceutical and biotech counterparties — and pursues lead generation through a business development team and presence at major industry conferences including BIO, ERS, CPHI, PODD, Bio-Europe, Jefferies Healthcare Conference, and DDL.
invoX Pharma firmographics
Firmographics- Name
- invoX Pharma
- Legal name
- invoX Pharma Limited
- Website
- https://invoxpharma.com/
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- invoX Pharma is a private biopharmaceutical company that develops and partners drug-device combination products built on its proprietary Softhaler® soft-mist inhalation platform, targeting chronic respiratory diseases for pharmaceutical and biotech partners globally.
- Ownership category
- akta.pro rank
invoX Pharma industry classification
Industry- Product category
- Respiratory Drug-Device Combination Products
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Inhalers (MDI/DPI/SMI) (HLAHAIAI)
- akta.pro secondary industries
- Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ), Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where invoX Pharma is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
invoX Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Co-development Partnerships: Revenue generated through co-development partnerships where partners leverage the Softhaler® SMI platform for their late-stage or approved medicines. Partners can deliver innovative inhalation products for lifecycle management of existing products.
- Pipeline Licensing: Licensing of internal pipeline programs to external partners. invoX offers both unpartnered programs and technology capabilities available for out-licensing.
- Contract Manufacturing Services: Supply chain services covering development to pilot scale and pilot scale to commercial supply, across all aspects of device manufacture, assembly, sterile fill & finish, and product packaging.
- Generic Drug-Device Products: Commercialization of generic and innovative drug-device combination products using the Softhaler® platform. First-to-market generic solution opportunities.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
invoX Pharma product offering
Product offeringCore offering
invoX Pharma develops and manufactures proprietary soft-mist inhalation drug-device combination products based on its Softhaler® platform, targeting respiratory diseases including COPD, asthma, PAH, cystic fibrosis, and idiopathic pulmonary fibrosis. The company offers co-development partnerships, platform licensing, contract manufacturing services, and an internal pipeline of generic and innovative inhaled therapeutics, including biologics and nucleic acids.
Product overview
invoX Pharma is a research-driven biopharmaceutical company that operates as a platform-based business centered on its proprietary Softhaler® soft-mist inhalation device. The Softhaler® platform serves as the core technology for delivering propellant-free liquid-based formulations to the lungs. The company combines this device platform with a pipeline of generic and innovative drug-device combination products targeting respiratory diseases including COPD, asthma, PAH, CF, and IPF. The company also conducts biological molecule delivery research (peptides, nucleic acids, enzymes, antibodies) and offers platform partnering services for co-development and licensing. A key strategic strength is their end-to-end supply chain for complex drug-device manufacturing and development, with manufacturing partnerships including H&T Presspart for device sub-assembly production.
Differentiator
Problem solved
Functional benefit
Brands
- Softhaler®: A next-generation soft-mist inhalation device platform that uses differentiated technology to deliver propellant-free liquid-based formulation to the lung.
Products and services
- Softhaler® Soft-Mist Inhalation Platform A next-generation soft-mist inhalation (SMI) device platform that mechanically converts liquid formulations into ultra-fine mist for propellant-free, deep lung delivery, supporting small molecules and complex biologics such as peptides, nucleic acids, enzymes, and antibodies. It is offered to pharmaceutical and biotech partners for generic and innovative drug-device combination products.
- Respiratory Drug Pipeline
Quantifiable outcome
- Better lung delivery and less deposition in mouth or at back of throat compared to other inhalers
- +1 more outcomes
Companies that use invoX Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
invoX Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
invoX Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- H&T Presspart (Heitkamp & Thumann Group)coreStrategic collaboration where H&T Presspart manufactures the device sub-assembly for commercialization of invoX's Softhaler® soft mist inhalation device. H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain. This is invoX's designated industrialisation and manufacturing partnership.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
invoX Pharma competitors and assessment
Company assessmentDirect peers
- Boehringer Ingelheim: Boehringer Ingelheim's Respimat is the established soft-mist inhaler (SMI) platform powering blockbusters such as Spiriva. As the dominant SMI incumbent, it is the most directly comparable competitor to invoX's Softhaler® platform in respiratory drug-device delivery.
- Vectura Group: Vectura is a specialist inhalation drug-device CDMO and development company offering DPI, nebulizer, and SMI platforms to partners. It is a direct comparable as a platform-based inhalation delivery business serving pharma partners, the same business model invoX pursues with Softhaler®.
- Hovione: Hovione is a CDMO with strong capabilities in inhalation drug product development and manufacturing, including particle engineering for DPI/nebulizer formulations. It is comparable to invoX on the contract manufacturing and formulation side of the inhalation value chain.
- Aptar Pharma: Aptar Pharma is a leading drug delivery device manufacturer with significant inhalation platform offerings (e.g., pMDI valves, DPI devices). It is a direct peer as a device-platform supplier serving the same respiratory pharma customer base invoX targets with Softhaler®.
- Nemera: Nemera designs and manufactures drug delivery devices including inhalation and nasal platforms for pharma partners. It overlaps with invoX on device-platform partnering for respiratory and combination products.
Broad incumbents
- Catalent: Catalent is a large CDMO offering inhalation development and manufacturing services alongside a much broader pharma services portfolio. It is comparable to invoX's contract manufacturing and supply-chain services but at far greater scale and breadth.
- GlaxoSmithKline (GSK): GSK is a top-three respiratory pharma major with proprietary inhaler platforms (e.g., Ellipta DPI) and a large commercial respiratory franchise. It is a broad incumbent competitor for both the Softhaler® platform's pharma partners and the same patient indications (COPD, asthma).
- AstraZeneca: AstraZeneca is a leading respiratory pharma player with products across COPD, asthma, and severe asthma, and operates inhalation device platforms via partners. It is comparable as a major incumbent whose franchise and partnerships invoX would compete against for Softhaler® adoption.
Emerging players
- Pulmatrix: Pulmatrix is a clinical-stage biopharma developing inhaled therapies for respiratory and infectious diseases using its iSPERSE dry powder technology. It is comparable as a smaller, emerging player focused on inhaled drug delivery for serious respiratory indications.
- Aradigm: Aradigm developed the AERx inhaled drug delivery platform and pursued inhaled liposomal therapies for respiratory disease. It is comparable as an emerging/specialized player in the inhaled respiratory therapeutics space, though narrower in platform scope than invoX.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
invoX Pharma social profiles
Digital presenceinvoX Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
invoX Pharma leadership team
Management profileNumber of profiles
Profiles11 records
invoX Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
invoX Pharma M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about invoX Pharma
What does invoX Pharma do?
invoX Pharma develops and manufactures proprietary soft-mist inhalation drug-device combination products based on its Softhaler® platform, targeting respiratory diseases including COPD, asthma, PAH, cystic fibrosis, and idiopathic pulmonary fibrosis. The company offers co-development partnerships, platform licensing, contract manufacturing services, and an internal pipeline of generic and innovative inhaled therapeutics, including biologics and nucleic acids.
Is invoX Pharma a public or private company?
invoX Pharma is a private company. It is classified as unknown and is currently operating.
When was invoX Pharma founded?
invoX Pharma was founded in 2021. It employs 11 to 50 people.
Where is invoX Pharma based?
invoX Pharma is headquartered in London, United Kingdom, in the Europe region.
How does invoX Pharma make money?
Four revenue lines are on record. Co-development Partnerships are the primary driver. The others are pipeline Licensing, contract Manufacturing Services and generic Drug-Device Products.
Who are invoX Pharma's main competitors?
Direct peers on record are Boehringer Ingelheim, Vectura Group, Hovione, Aptar Pharma and Nemera. Broad incumbents are Catalent, GlaxoSmithKline (GSK) and AstraZeneca. Emerging players are Pulmatrix and Aradigm.
Does invoX Pharma have an API?
No public API is recorded for invoX Pharma.
What industry is invoX Pharma in?
invoX Pharma's product category is Respiratory Drug-Device Combination Products. Its primary akta.pro industry code is HLAHAIAI, Inhalers (MDI/DPI/SMI), with a secondary code of HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems. Its NAICS code is 32541 and its SIC code is 2834.